Literature DB >> 20512160

Therapeutic exon 'switching' for dysferlinopathies?

Nicolas Lévy, Nicolas Wein, Florian Barthelemy, Vincent Mouly, Luis Garcia, Martin Krahn, Marc Bartoli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20512160      PMCID： PMC2987414          DOI： 10.1038/ejhg.2010.73

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN： 1018-4813            Impact factor:   4.246


× No keyword cloud information.
  3 in total

1.  Lariat branch point mutation in the dysferlin gene with mild limb-girdle muscular dystrophy.

Authors:  Michael Sinnreich; Christian Therrien; George Karpati
Journal:  Neurology       Date:  2006-04-11       Impact factor: 9.910

2.  Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping.

Authors:  Nicolas Wein; Aurélie Avril; Marc Bartoli; Cyriaque Beley; Soraya Chaouch; Pascal Laforêt; Anthony Behin; Gillian Butler-Browne; Vincent Mouly; Martin Krahn; Luis Garcia; Nicolas Lévy
Journal:  Hum Mutat       Date:  2010-02       Impact factor: 4.878

Review 3.  Progress in therapeutic antisense applications for neuromuscular disorders.

Authors:  Annemieke Aartsma-Rus; Gert-Jan B van Ommen
Journal:  Eur J Hum Genet       Date:  2009-10-07       Impact factor: 4.246
  3 in total
  2 in total

Review 1.  Translational research and therapeutic perspectives in dysferlinopathies.

Authors:  Florian Barthélémy; Nicolas Wein; Martin Krahn; Nicolas Lévy; Marc Bartoli
Journal:  Mol Med       Date:  2011-05-06       Impact factor: 6.354

2.  Inhibition of inflammation with celastrol fails to improve muscle function in dysferlin-deficient A/J mice.

Authors:  Blythe C Dillingham; Margaret E Benny Klimek; Ramkishore Gernapudi; Sree Rayavarapu; Eduard Gallardo; Jack H Van der Meulen; Sarah Jordan; Beryl Ampong; Heather Gordish-Dressman; Christopher F Spurney; Kanneboyina Nagaraju
Journal:  J Neurol Sci       Date:  2015-06-24       Impact factor: 3.181
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.